Baldwin Insurance Group and Beta Bionics see market activity

Baldwin Insurance Group (NASDAQ: BWIN) has seen several adjustments to its stock price targets by various analysts. BMO Capital Markets raised its objective to $32.50, while UBS Group increased its target to $37.00 with a “buy” rating. Other firms, including JPMorgan Chase & Co., Wells Fargo & Company, and Keefe, Bruyette & Woods, have also issued updated price targets and ratings. The stock recently experienced a gap up in its opening price.

Beta Bionics (NASDAQ: BBNX) is conducting an underwritten public offering of common shares and pre-funded warrants, which is expected to raise approximately $150 million in gross proceeds. The company intends to use the funds for general corporate purposes, including the commercialization of Mint, manufacturing expansion, and research and development.

In related analyst activity, Robert W. Baird raised its price target for Beta Bionics to $16.00. Other institutions, including Goldman Sachs and Truist Financial, have also issued updated ratings and price objectives for the company.